251 related articles for article (PubMed ID: 1903991)
1. Adherent lymphokine-activated killer cells suppress autologous human normal bone marrow progenitors.
Miller JS; Verfaillie C; McGlave P
Blood; 1991 Jun; 77(11):2389-95. PubMed ID: 1903991
[TBL] [Abstract][Full Text] [Related]
2. Diminished A-LAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia.
Verfaillie C; Kay N; Miller W; McGlave P
Blood; 1990 Jul; 76(2):401-8. PubMed ID: 1695114
[TBL] [Abstract][Full Text] [Related]
3. Assay of lymphokine-activated killer activity generated from bone marrow cells of children with acute lymphoblastic leukemia.
Zhou MX; Findley HW; Davis R; Ragab AH
Blood; 1990 Jan; 75(1):160-5. PubMed ID: 2294987
[TBL] [Abstract][Full Text] [Related]
4. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
5. Adherent lymphokine-activated killer cells in chronic myelogenous leukemia: a benign cell population with potent cytotoxic activity.
Verfaillie C; Miller W; Kay N; McGlave P
Blood; 1989 Aug; 74(2):793-7. PubMed ID: 2473805
[TBL] [Abstract][Full Text] [Related]
6. NK and LAK activities from human marrow progenitors. I. The effects of interleukin-2 and interleukin-1.
Keever CA; Pekle K; Gazzola MV; Collins NH; Gillio A
Cell Immunol; 1990 Mar; 126(1):211-26. PubMed ID: 1689220
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor cytotoxic potential and effect on human bone marrow GM-CFU of human LAK cells generated in response to various cytokines.
Parhar RS; Ernst P; Sheth KV; al-Sedairy ST
Eur Cytokine Netw; 1992; 3(3):299-306. PubMed ID: 1498260
[TBL] [Abstract][Full Text] [Related]
8. Lymphokine-activated killer cells selectively kill tumor cells in bone marrow without compromising bone marrow stem cell function in vitro.
van den Brink MR; Voogt PJ; Marijt WA; van Luxemburg-Heys SA; van Rood JJ; Brand A
Blood; 1989 Jul; 74(1):354-60. PubMed ID: 2787676
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients: II. Feasibility of LAK generation in children with active disease and in remission.
Adler A; Albo V; Blatt J; Whiteside TL; Herberman RB
Blood; 1989 Oct; 74(5):1690-7. PubMed ID: 2790193
[TBL] [Abstract][Full Text] [Related]
10. Interferon-gamma (IFN-gamma) and interleukin-2 in the generation of lymphokine-activated killer cell cytotoxicity--IFN-gamma-induced suppressive activity.
Toledano M; Mathiot C; Michon J; Andreu G; Lando D; Brandely M; Fridman WH
Cancer Immunol Immunother; 1989; 30(1):57-64. PubMed ID: 2513112
[TBL] [Abstract][Full Text] [Related]
11. High release of tumor necrosis factor alpha, interferon gamma and interleukin-6 by adherent lymphokine-activated killer cells phenotypically derived from T cells.
Koberda J; Bergmann L; Mitrou PS; Hoelzer D
J Cancer Res Clin Oncol; 1991; 117(5):425-30. PubMed ID: 1909699
[TBL] [Abstract][Full Text] [Related]
12. Effect of granulocyte-macrophage colony-stimulating factor on lymphokine-activated killer cell induction.
Stewart-Akers AM; Cairns JS; Tweardy DJ; McCarthy SA
Blood; 1993 May; 81(10):2671-8. PubMed ID: 8490177
[TBL] [Abstract][Full Text] [Related]
13. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells.
Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC
J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622
[TBL] [Abstract][Full Text] [Related]
14. The effect of anti-CD3 on the induction of non-MHC restricted cytolytic activity.
Watanabe H; Narumi K; Stewart CC; Arbuck SG; Foon KA; Goldrosen MH
Anticancer Res; 1992; 12(6B):1925-33. PubMed ID: 1295440
[TBL] [Abstract][Full Text] [Related]
15. Lymphokine-activated effector cells: modulation of activity by cytokines.
Mehta S; Flanagan P; Blackinton D; Wanebo H
Lymphokine Cytokine Res; 1992 Apr; 11(2):73-7. PubMed ID: 1581419
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-2 modulates the expression of lymphocyte function-associated antigen-one (LFA-1) and p150,95 during the generation of lymphokine-activated killer (LAK) cells.
Grant AJ; Merchant RE; Hall RE
Immunology; 1989 Jan; 66(1):117-24. PubMed ID: 15493273
[TBL] [Abstract][Full Text] [Related]
17. Effects of recombinant human tumor necrosis factor on highly enriched hematopoietic progenitor cell populations from normal human bone marrow and peripheral blood and bone marrow from patients with chronic myeloid leukemia.
Wisniewski D; Strife A; Atzpodien J; Clarkson BD
Cancer Res; 1987 Sep; 47(18):4788-94. PubMed ID: 3040231
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of suppression of normal hemopoietic activity by lymphokine-activated killer cells and their products.
Gibson FM; Malkovska V; Myint AA; Meager A; Gordon-Smith EC
Exp Hematol; 1991 Aug; 19(7):659-63. PubMed ID: 1909968
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneous lymphokine-activated killer cell precursor populations. Development of a monoclonal antibody that separates two populations of precursors with distinct culture requirements and separate target-recognition repertoires.
Fox BA; Rosenberg SA
Cancer Immunol Immunother; 1989; 29(3):155-66. PubMed ID: 2786456
[TBL] [Abstract][Full Text] [Related]
20. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
